Abstract:Alzheimer's disease (AD) is the leading cause of dementia, afflicting 5 million Americans and costing over 200 billion dollars per year. The mechanisms involved in AD pathogenesis are still poorly understood. Moreover, no therapy is available to cure AD or to slow down its progression. The study of new pathways involved in AD pathogenesis is necessary to develop new therapeutic targets. The 12/15-lipoxygenase enzymatic pathway (12/15-LO) is upregulated in postmortem brain tissues and cerebrospinal fluid of AD patients. Its genetic absence or pharmacological inhibition prevents the development of the AD-like phenotype in transgenic mouse models of the disease. However, whether targeting pharmacologically this pathway after the neuropathological lesions and behavioral impairments are well established could be a viable therapeutic strategy against AD remain to be investigated. To this end, 12-month-old triple transgenic mice (3xTg) and their appropriate wild type controls were randomized to receive a specific and selective pharmacological inhibitor of 12/15-LO, PD146176, or placebo. After 3 months, when the animals were 15-month-old, treated and untreated groups were assessed for the effects of the drug on their behavioral impairments and neuropathology. While 15-month-old 3xTg mice on placebo by the end of the study showed a worsening of their memory and learning abilities, as assessed by the fear conditioning paradigms, mice at the same age receiving the PD146176 performed better than baseline in the same test. Compared with placebo, treated mice had significantly less Abeta levels and deposition, improved tau pathology as well as markers of synaptic integrity. Additionally, the same PD146176 treated animals showed a significant upregulation of autophagy markers, suggesting an involvement of this pathway in the pharmacological effect. In vitro experiments demonstrated that 12/15-LO effect on tau metabolism is mediated by modulating neuronal autophagy system. These studies provide new insights into the disease-modifying action of pharmacological inhibiting 12/15-LO as a viable therapeutic approach for AD treatment. They represent the successful completion of the preclinical studies for the development of this class of drug as clinically applicable therapy for the disease.

Anti-LINGO-1 antibody ameliorates cognitive impairment, promotes adult hippocampal neurogenesis, and increases the abundance of CB1R-rich CCK-GABAergic interneurons in AD mice

Anti-LINGO-1 antibody treatment alleviates cognitive deficits and promotes maturation of oligodendrocytes in the hippocampus of APP/PS1 mice

Antagonizing LINGO-1 reduces activated microglia and alleviates dendritic spine loss in the hippocampus of APP/PS1 transgenic mice

LINGO‐1 Antibody Ameliorates Myelin Impairment and Spatial Memory Deficits in the Early Stage of 5XFAD Mice

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

The Neuroprotective Effect of Neural Cell Adhesion Molecule L1 in the Hippocampus of Aged Alzheimer's Disease Model Mice

A New Chiral Pyrrolyl α-Nitronyl Nitroxide Radical Attenuates β-Amyloid Deposition and Rescues Memory Deficits in a Mouse Model of Alzheimer Disease

Tetradecyl 2,3-Dihydroxybenzoate Improves Cognitive Function in AD Mice by Modulating Autophagy and Inflammation Through IPA and Hsc70 Targeting

LINGO-1 Antibody Ameliorates Myelin Impairment and Spatial Memory Deficits in Experimental Autoimmune Encephalomyelitis Mice

Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models

Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model

A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice

Ginsenoside Rg1 alleviates learning and memory impairments and Aβ disposition through inhibiting NLRP1 inflammasome and autophagy dysfunction in APP/PS1 mice

Angiotensin-(1–7) Analogue AVE0991 Modulates Astrocyte-Mediated Neuroinflammation via lncRNA SNHG14/miR-223-3p/NLRP3 Pathway and Offers Neuroprotection in a Transgenic Mouse Model of Alzheimer’s Disease

Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer’s Disease

12/15-LIPOXYGENASE INHIBITION REVERSES COGNITIVE IMPAIRMENT, AMYLOIDOSIS, TAU AND SYNAPTIC PATHOLOGY BY STIMULATING AUTOPHAGY IN THE BRAIN OF AGED 3XTG MICE

Adhesion molecule L1 binds to amyloid beta and reduces Alzheimer's disease pathology in mice

20(S)-protopanaxadiol and oleanolic acid ameliorate cognitive deficits in APP/PS1 transgenic mice by enhancing hippocampal neurogenesis

Polysaccharides from Lycium Barbarum Ameliorate Amyloid Pathology and Cognitive Functions in APP/PS1 Transgenic Mice.

Title Blocking LINGO-1 in vivo reduces degeneration and enhancesregeneration of the optic nerve

Cognitive enhancement and neuroprotective effects of OABL, a sesquiterpene lactone in 5xFAD Alzheimer's disease mice model